NEW YORK (GenomeWeb News) – ChanTest is collaborating with the US Food and Drug Administration to develop assays to improve prediction of cardiac safety, the company announced on Thursday.
Under the deal with the FDA's Center for Drug Evaluation and Research, the Cleveland-based firm will develop non-clinical assays, databases, and computational models for assessing the risk of serious cardiac events associated with drug-induced QT prolongation. Research will also be done to identify gaps in current safety testing methods for new drugs.
Terms of the deal were not disclosed.
In a statement, ChanTest said that the hERG assay, a primary method of classifying investigational drugs with the potential to prolong the QT interval, is generally viewed as being insufficiently sensitive and specific to predict the clinical risk of QT prolongation and serious ventricular arrhythmia accurately across all chemical and drug classes. While seeking to identify gaps in current safety testing, the collaboration will improve understanding of the cellular basis for serious clinical events associated with QT prolongation, it said.
ChanTest offers ion channel and GPCR screening services to research and drug discovery and development customers.